Patent · US Active

Combination therapy of an HBV capsid assembly inhibitor and an interferon

US10596173B2 · kind B2 · utility

8Cited by

2References

25Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Lu Gao · Shanghai, CN
Isabel Najera · Menlo Park, US
Hong Shen · Shanghai, CN
Fang Shen · Amherst, US
Liping Shi · Shanghai, CN
Steffen Wildum · Gevelsberg, DE
Guang Yang · Nanhu, CN

Key dates

Filing date	May 3, 2018
Grant date	Mar 24, 2020
Priority date	—
Expiry date	May 3, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2300/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and an interferon for use in the treatment of hepatitis B virus infections.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.